Moore David M, Mermin Jonathan, Awor Anna, Yip Benita, Hogg Robert S, Montaner Julio S G
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):436-9. doi: 10.1097/01.qai.0000243105.80393.42.
World Health Organization (WHO) guidelines for the use of antiretroviral therapy (ART) in resource-limited settings state that CD4 cell counts may be used to indicate when ART regimens should be changed because of treatment failure. The performance of immunologic monitoring for this purpose has not been evaluated, however.
Participants aged > or =18 years from the British Columbia HIV/AIDS Drug Treatment Program who had CD4 cell counts < or =200 cells/microL or an AIDS diagnosis at baseline had CD4 cell counts measured at 6 and 12 months after treatment initiation. Logistic regression analysis was used to calculate sensitivity, specificity, and positive and negative predictive values for immunologic responses in terms of predicting failure to achieve 2 viral load measurements < 500 copies/mL within 1 year.
Viral load suppression occurred in 674 (60%) of 1125 subjects. Using no increase in CD4 cell counts at 6 months as a definition of treatment failure had a sensitivity of 34%, specificity of 94%, positive predictive value of 75%, and negative predictive value of 71% for predicting failure to achieve virologic suppression. Using 12-month CD4 cell count values, the measurements were 35%, 95%, 79%, and 73%, respectively.
Immunologic criteria to predict which patients have not achieved virologic suppression results in significant misclassification of therapeutic responses.
世界卫生组织(WHO)关于在资源有限环境中使用抗逆转录病毒疗法(ART)的指南指出,CD4细胞计数可用于指示何时应因治疗失败而更改ART方案。然而,尚未评估用于此目的的免疫监测的性能。
来自不列颠哥伦比亚省HIV/艾滋病药物治疗项目的年龄≥18岁、基线时CD4细胞计数≤200个/微升或被诊断为艾滋病的参与者在开始治疗后6个月和12个月测量CD4细胞计数。逻辑回归分析用于计算免疫反应在预测1年内未能实现2次病毒载量测量<500拷贝/毫升方面的敏感性、特异性、阳性预测值和阴性预测值。
1125名受试者中有674名(60%)实现了病毒载量抑制。将6个月时CD4细胞计数未增加作为治疗失败的定义,在预测未能实现病毒学抑制方面的敏感性为34%,特异性为94%,阳性预测值为75%,阴性预测值为71%。使用12个月时的CD4细胞计数,相应的测量值分别为35%、95%、79%和73%。
用于预测哪些患者未实现病毒学抑制的免疫标准会导致治疗反应的显著错误分类。